Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer
Executive Summary
National Cancer Institute's Phase II combo data for AstraZeneca's PARP inhibitor Lynparza and PD-L1 inhibitor Imfinzi are encouraging, but more research is needed to show a role for immunotherapy combinations in advanced prostate cancer.